4613347870

RE E CS

Adair, R.A., Scott, K.J., Fraser, S., Errington-Mais, F., Pandha, H., Coffey, M., Selby, P., Cook, G.P., Vile, R., Harrington, K.J., et al. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int. J. Cancer 752,2327-2338.

Aguirre-Ghiso, J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Naturę Reviews Cancer 7, 834-846.

Ahmed, M., and Lyles, D.S. (1998). Effect of Vesicular Stomatitis Virus matrix protein on transcription directed by host RN A polymerases I, II, and III. J. Virol. 72, 8413-8419.

Ahmed, M., McKenzie, M.O., Puckett, S., Hojnacki, M., Poliąuin, L., and Lyles, D.S. (2003). Ability of the matrix protein of Vesicular Stomatitis Virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77,4646-4657.

Ahmed, M., Mitchell, L.M., Puckett, S., Brzoza-Lewis, K.L., Lyles, D.S., and Hiltbold, E.M (2009). Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J. Virol. 83,2962-2975.

Ahmed, M., Puckett, S., and Lyles, D.S. (2010). Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther 17, 883-892.

Albertini, A.A.V., Baąuero, E., Ferlin, A., and Gaudin, Y (2012). Molecular and cellular aspects of Rhabdovirus entry. Viruses 4, 117-139.

Allendorf, D.J., Yan, J., Ross, G.D., Hansen, R.D., Baran, J.T, Subbarao, K., Wang, L, and Haribabu, B. (2005). C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and P-Glucan. The Journal of Immunology 174, 7050 7056.

Andersen, C., Jensen, T., Nansen, A., Marker, O., and Thomsen, A.R. (1999). CD4+ T cell-mediated protection against a lethal outcome of systemie infection with vesicular stomatitis virus requires CD40 ligand expression, but not IFN-y or IL-4. Int. Immunol. 77,2035-2042.

182